What is Rapport Therapeutics, Inc.'s SG&A?

Rapport Therapeutics, Inc. (RAPP) reported SG&A of $11.5M in Q1 2026.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Rapport Therapeutics, Inc. RAPP SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

Supernus PharmaceuticalsSUPN

$125.17M+39.2%

Acadia PharmaceuticalsACAD

$171.02M+35.3%

Catalyst PharmaceuticalCPRX

$49.32M+5.1%

BioCryst PharmaceuticalsBCRX

$94.55M+14.7%

Arrowhead ResearchARWR

——

Segments

By product

See full

Professional And Consulting Costs$3.67M+121%

Facility Related And Other$844K-7.6%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.86B+309%

Enterprise value$1.79B+352%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s SG&A?: Rapport Therapeutics, Inc. (RAPP) reported SG&A of $11.5M in Q1 2026.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.